Description of oncological outcomes and toxicity in gastric cancer patients treated with concomitant adjuvant three-dimensional conformal radiotherapy and chemotherapy (3DCRT), at the National Cancer Institute
DOI:
https://doi.org/10.35509/01239015.784Keywords:
gastric cancer, radiotherapy, 3DCRT technical radiotherapyAbstract
Introduction: In 2018, gastric cancer was the fifth most frequent cancer, being the third cause of mortality in the world. Although there is no standard treatment for this cancer, it is known that surgery is the mainstay of treatment, however, without adjuvant treatments it can have a poor overall survival. The most widely used protocols after surgery are the Macdonald and the Artist. The objective of this study is to show the results in disease-free survival and overall survival that were taken to surgery and adjuvant chemo-radiotherapy with the 3DCRT technique of the National Cancer Institute. Materials and methods: A descriptive, retrospective cohort study was carried out, which included 51 patients, older than 18 years, with no evidence of metastatic disease, who were treated with adjuvant chemo-radiotherapy between 2010 and 2015. Findings: The median age was 61 years. At 60 months of follow-up, ten patients presented relapse, of which eight were distant, one regional and the other local. A 5-year overall survival of 58% and disease-free survival of 69.8% were also found. Conclusion: Treatment with radiotherapy with 3DRT technique concomitant with chemotherapy, in patients with gastric cancer taken to adjuvant management, is effective. With a disease-free survival of 69.8% and an overall 5-year survival of 58%, which are comparable to, and even superior to, the oncological results obtained in the Macdonald and Artist protocols.
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6): 394-424. https://doi.org/10.3322/caac.21492.
Heberer G, Teichmann RK, Krämling HJ, Günther B. Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg [Internet]. 1988 Jun [cited 2015 Oct 8];12(3):374–81. https://doi.org/10.1007/BF01655678.
Soon YY, Leong CN, Tey JCS, Tham IWK, Lu JJ. Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: A systematic review and meta-analysis. J Med Imaging Radiat Oncol [Internet]. 2014;58:n/a – n/a. https://doi.org/10.1111/1754-9485.12190
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M. et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20. https://doi.org/10.1056/NEJMoa055531.
Al-Batran, S. E., Homann, N., Schmalenberg, H., Kopp, H. G., Haag, G. M., Luley, K. B. et al. (2017). Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A. et al. (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New England Journal of Medicine, 357(18), 1810-1820. https://doi.org/10.1056/NEJMoa072252.
Bang, Y. J., Kim, Y. W., Yang, H. K., Chung, H. C., Park, Y. K., Lee, K. H. et al. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet, 379(9813), 315-321. https://doi.org/10.1016/S0140-6736(11)61873-4.
Macdonald JS, Smalley SR, Benedetti J, Hundahl S a, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. https://doi.org/10.1056/NEJMoa010187.
Lee J, Lim Dh, Kim S, Park SH, Park JO, Park YS et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. https://doi.org/10.1200/JCO.2011.39.1953.
Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim K-M, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol [Internet]. 2015;33(28):3130–6. https://doi.org/10.1200/JCO.2014.58.3930.
Cochrane Database Syst Rev. 2015 Aug 12;(8):CD001964. Extent of lymph node dissection for adenocarcinoma of the stomach. https://doi.org/10.1002/14651858.CD001964.pub4.
Morganti AG, Di Castelnuovo A, Massaccesi M, Cellini F, Cilla S, Macchia G, et al. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. Br J Radiol [Internet]. 2013 Sep [cited 2015 Oct 8];86(1029):20130274. https://doi.org/10.1259%2Fbjr.20130274.
El-Hossiny HA, Diab NA, El-Taher MM. A Comparative Dosimetric Study of Adjuvant 3D Conformal Radiotherapyfor Operable Stomach Cancer Versus AP-PA Conventional Radiotherapy in NCI-Cairo. J Egypt Natl Canc Inst [Internet]. 2009 Sep [cited 2015 Oct 19];21(3):197–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21132029.
Nicolas Isa O., Moises Russo N, Hernán López V. Radioquimioterapia adyuvante en cáncer gástrico completamente resecado: experiencia del Instituto Nacional del Cáncer de Chile - Rev. méd. Chile vol.142 no.2 Santiago feb. 2014. https://doi.org/10.4067/S0034-98872014000200008.
Huang, S. M., Chen, Y. C., Chen, W. Y., Yang, L. Y., Tsan, D. L., Tsang, N. M, et al. (2019). Optimal timing for postsurgical adjuvant therapy in patients with gastric Cancer: a propensity score matching study. Journal of Cancer, 10(2), 332. https://doi.org/10.7150/jca.27753.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Revista Colombiana de Cancerología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los derechos reservados.
